Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC).

10.1200/jco.2010.28.15_suppl.7580 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7580-7580 ◽

Cited By ~ 1

Author(s):

R. Govindan ◽

C. Zergebel ◽

K. Saito ◽

J. H. Schiller

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy ◽

A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non–Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial

Clinical Lung Cancer ◽

10.1016/j.cllc.2014.06.010 ◽

2015 ◽

Vol 16 (1) ◽

pp. 57-59 ◽

Cited By ~ 11

Author(s):

Morena Fasano ◽

Carminia Maria Della Corte ◽

Annalisa Capuano ◽

Ferdinando Carlo Sasso ◽

Federica Papaccio ◽

...

Keyword(s):

Phase Ii Study ◽

Stage Iv ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Lung Cancer Patients ◽

Line Therapy ◽

Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

10.1200/jco.2005.23.16_suppl.7035 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 7035-7035 ◽

Cited By ~ 7

Author(s):

T. Cufer ◽

E. Vrdoljak

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Phase II study of cabazitaxel as second-line therapy in stage IV non-small cell lung cancer (NSCLC).

10.1200/jco.2014.32.15_suppl.e19107 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e19107-e19107

Author(s):

Devika Das ◽

Francisco Robert ◽

Rodolfo Bordoni ◽

Stefan C. Grant ◽

Mansoor N. Saleh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iv ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer

Lung Cancer ◽

10.1016/j.lungcan.2013.02.007 ◽

2013 ◽

Vol 80 (3) ◽

pp. 319-325 ◽

Cited By ~ 7

Author(s):

David F. Heigener ◽

Joachim von Pawel ◽

Corinna Eschbach ◽

Andreas Brune ◽

Alexander Schmittel ◽

...

Keyword(s):

Phase Ii Study ◽

Small Cell ◽

Independent Group ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy ◽

PD-070 SIGN: A Phase II, open-label, randomized study comparinggefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Lung Cancer ◽

10.1016/s0169-5002(05)80403-9 ◽

2005 ◽

Vol 49 ◽

pp. S87 ◽

Cited By ~ 1

Author(s):

T. Cufer ◽

E. Vrdoljak

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

6568 POSTER Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71396-4 ◽

2007 ◽

Vol 5 (4) ◽

pp. 378 ◽

Cited By ~ 10

Author(s):

U. Gatzemeier ◽

J. vonPawel ◽

C. Eschbach ◽

A. Brune ◽

A. Wagner ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Stage Iv ◽

Small Cell ◽

The Novel ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

An evaluation of systemic therapy beyond second-line therapy in patients with stage IV non-small cell lung cancer.

10.1200/jco.2015.33.15_suppl.e19129 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e19129-e19129

Author(s):

Ahmed Ashour Badawy ◽

Sejong Bae ◽

Stefan C. Grant

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Systemic Therapy ◽

Stage Iv ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.1016/j.cllc.2014.10.001 ◽

2015 ◽

Vol 16 (2) ◽

pp. 92-99 ◽

Cited By ~ 10

Author(s):

Cornelius F. Waller ◽

Ihor Vynnychenko ◽

Igor Bondarenko ◽

Yaroslav Shparyk ◽

Jeffrey P. Hodge ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Eribulin Mesylate ◽

Phase Ib ◽

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Anti-Cancer Drugs ◽

10.1097/01.cad.0000203381.99490.ab ◽

2006 ◽

Vol 17 (4) ◽

pp. 401-409 ◽

Cited By ~ 100

Author(s):

Tanja Cufer ◽

Eduard Vrdoljak ◽

Rabab Gaafar ◽

Inci Erensoy ◽

Kristine Pemberton

Keyword(s):

Lung Cancer ◽

Randomized Study ◽

Single Agent ◽

Small Cell ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽